Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

J. Gradishar, William; O. Anderson, Benjamin; Abraham, Jame; Aft, Rebecca; Agnese, Doreen; H. Allison, Kimberly; L. Blair, Sarah; J. Burstein, Harold; Dang, Chau; D. Elias, Anthony; H. Giordano, Sharon; P. Goetz, Matthew; J. Goldstein, Lori; J. Isakoff, Steven; Krishnamurthy, Jairam; Lyons, Janice; Kelly Marcom, P.; Matro, Jennifer; A. Mayer, Ingrid; S. Moran, Meena; Mortimer, Joanne; M. O'Regan, Ruth; A. Patel, Sameer; J. Pierce, Lori; S. Rugo, Hope; Sitapati, Amy; Lisa Smith, Karen; Lou Smith, Mary; Soliman, Hatem; M. Stringer-Reasor, Erica; L. Telli, Melinda; H. Ward, John; S. Young, Jessica; L. Burns, Jennifer; Kumar, Rashmi

doi:10.6004/jnccn.2020.0016

Public

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Shared by NobleBlocks on Apr 1, 2020 • 12:00 AM UTC

Authors:

William J. Gradishar

Benjamin O. Anderson

Jame Abraham

Abstract

Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). Th...

Discussions